Prevent Blindness Organization defines Uveitis as, a term for inflammation of the eye. It is an inflammation of the uvea, the pigmented layer that lies between the inner retina and the outer fibrous layer composed of the sclera and cornea. It is caused by inflammatory responses inside the eye that can be caused due to tissue damage, germs, or toxins which lead to swelling, redness, heat, and destroys tissues as certain white blood cells rush to the affected part.
Uveitis is classified anatomically as anterior, intermediate, posterior, or diffuse. Anterior uveitis typically refers to inflammation of the iris and anterior chamber; intermediate uveitis refers to inflammation of the ciliary body and vitreous humor (the jellylike filling in the anterior portion of the eye); and posterior uveitis refers to inflammation of the retina, choroid, or the optic disk (where the optic nerve enters the retina). Diffuse uveitis (Panuveitis) implies inflammation of the entire uveal tract.
Patients may present with concurrent systemic symptoms or infectious diseases to suggest an etiology affecting more than just the eye. Idiopathic cases of uveitis account for 48 to 70% of uveitis cases.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/uveitis-market
The Uveitis Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Uveitis market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Uveitis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Uveitis Market Key Facts
As per DelveInsight, the total prevalent cases of Uveitis in the US were observed to be 357,791 in 2017.
In 2017, Acute Anterior Uveitis was accounted for 43.00% of the total cases of Uveitis in the United States. Acute anterior noninfectious uveitis includes Grade 0 and 1 and accounts for 93,188 cases in 2017. While, in the same year, 123,528 cases of chronic anterior noninfectious uveitis out of which Grade 2 has 79,882 cases; Grade 3 has 29,777, and Grade 4 has 13,870 cases respectively.
The United States accounted for the maximum prevalent cases of NIU (Non-Infectious Uveitis) with around 277,573 prevalent cases in 2017, followed by Japan (94,043) and Germany (57,233).
The majority of cases of Uveitis are female as compared to males. There were a total of 154,190 female and 149,932 male cases of Uveitis in 2017 in the United States.
Key Benefits of Uveitis Market Report
Uveitis market report provides an in-depth analysis of Uveitis Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.
The report will help in developing business strategies by understanding the Uveitis Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.
The market report covers the Uveitis current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.
The report provides a detailed assessment of the Uveitis market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.
The therapeutic market of Uveitis in the seven major markets was USD 1027.0 million in 2017. The United States accounts for the highest market size of Uveitis, in comparison to the other 7 Major Markets i.e., EU5 countries (the United Kingdom, Germany, Italy, France, and Spain), and Japan. Among the EU5 countries, Germany had the highest market size, while Spain had the lowest market size of Uveitis.
As per DelveInsight, the market size of Uveitis shall grow during the forecast period owing to the launch of upcoming therapies, the increasing prevalent population of Uveitis, and the rise in awareness about the disease.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Uveitis market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Uveitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
The epidemiology section covers insights about the historical and current Uveitis patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Uveitis Epidemiology Segmentation
Total Prevalent Cases
Gender-Specific Diagnosed Prevalent Cases
Type-Specific Diagnosed Prevalent Cases
Age-Specific Diagnosed Prevalent Cases
Diagnosed Prevalence of Non- 5 infectious Uveitis (NIU) by Anatomical Location
Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU)
Uveitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Uveitis market or expected to get launched in the market during the study period. The analysis covers Uveitis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Uveitis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Uveitis market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for Uveitis emerging therapies.
And many others.
Uveitis Therapies covered in the report include:
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. Uveitis Competitive Intelligence Analysis
4. Uveitis Market Overview at a Glance
5. Uveitis Disease Background and Overview
6. Uveitis Patient Journey
7. Uveitis Epidemiology and Patient Population
8. Uveitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Uveitis Unmet Needs
10. Key Endpoints of Uveitis Treatment
11. Uveitis Marketed Products
12. Uveitis Emerging Therapies
13. Uveitis Seven Major Market Analysis
14. Attribute Analysis
15. Uveitis Market Outlook (7 major markets)
16. Uveitis Access and Reimbursement Overview
17. KOL Views on the Uveitis Market.
18. Uveitis Market Drivers
19. Uveitis Market Barriers
21. DelveInsight Capabilities
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/uveitis-market
Latest Reports By DelveInsight
Uveitis Pipeline Insights
Uveitis Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Uveitis market.
Healthcare Blog By DelveInsight-
Diabetic Macular Edema Market (DME Market)
The Diabetic Macular Edema Therapeutics Market is expected to witness a remarkable change owing to the launch of the novel therapies key companies such as Roche, Novartis, Adverum Biotechnologies, Graybug Vision, KalVista Pharmaceuticals, Ocuphire Pharma, Oxurion, YD Life Science, among others. To read more, visit: Diabetic Macular Edema Therapy Market
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States